Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pharmacoeconomics and clinical practice guidelines : A survey of attitudes in Swedish formulary committees

Anell, Anders LU and Svarvar, Patrick (2000) In PharmacoEconomics 17(2). p.175-185
Abstract

Background: Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. Objective: The purpose of this exploratory study was to identify the information sources and decision criteria that individual committee members perceive as important in establishing clinical practice guidelines. Moreover, obstacles to the increased use of pharmacoeconomic evaluations in decision-making were also identified. Design and setting: Data were gathered through a survey questionnaire administered in 1998 to members of central... (More)

Background: Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. Objective: The purpose of this exploratory study was to identify the information sources and decision criteria that individual committee members perceive as important in establishing clinical practice guidelines. Moreover, obstacles to the increased use of pharmacoeconomic evaluations in decision-making were also identified. Design and setting: Data were gathered through a survey questionnaire administered in 1998 to members of central formulary committees throughout Sweden, as determined by a national register. Participants: 312 members of central formulary committees, of whom 69% responded. Results: Treatment policies/guidelines supplied by government authorities, or found in reviewed journals, are considered the most important sources of information, and criteria associated with costs and effects are considered the most important decision criteria. The members' years of experience and their professions affect their assessments of information sources, whereas education in health economics affects their assessments of decision criteria. Committee members voiced an interest in pharmacoeconomic issues, but warned that there was neither sufficient competence among committee members nor an adequate supply of relevant studies. Furthermore, a majority of the members identified difficulty in translating study results into clinical practice guidelines and limited possibilities in comparing studies as obstacles to the increased use of pharmacoeconomic evaluations. Conclusions: The results of this survey may be useful in designing future economic evaluations and when presenting and diffusing study results.

(Less)
Please use this url to cite or link to this publication:
author
and
publishing date
type
Contribution to journal
publication status
published
subject
in
PharmacoEconomics
volume
17
issue
2
pages
11 pages
publisher
Adis International
external identifiers
  • pmid:10947340
  • scopus:0034066564
ISSN
1170-7690
DOI
10.2165/00019053-200017020-00006
language
English
LU publication?
no
id
e3e568f5-240d-490b-b29a-5d450d533f8c
date added to LUP
2020-09-02 13:21:53
date last changed
2024-01-02 17:32:29
@article{e3e568f5-240d-490b-b29a-5d450d533f8c,
  abstract     = {{<p>Background: Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. Objective: The purpose of this exploratory study was to identify the information sources and decision criteria that individual committee members perceive as important in establishing clinical practice guidelines. Moreover, obstacles to the increased use of pharmacoeconomic evaluations in decision-making were also identified. Design and setting: Data were gathered through a survey questionnaire administered in 1998 to members of central formulary committees throughout Sweden, as determined by a national register. Participants: 312 members of central formulary committees, of whom 69% responded. Results: Treatment policies/guidelines supplied by government authorities, or found in reviewed journals, are considered the most important sources of information, and criteria associated with costs and effects are considered the most important decision criteria. The members' years of experience and their professions affect their assessments of information sources, whereas education in health economics affects their assessments of decision criteria. Committee members voiced an interest in pharmacoeconomic issues, but warned that there was neither sufficient competence among committee members nor an adequate supply of relevant studies. Furthermore, a majority of the members identified difficulty in translating study results into clinical practice guidelines and limited possibilities in comparing studies as obstacles to the increased use of pharmacoeconomic evaluations. Conclusions: The results of this survey may be useful in designing future economic evaluations and when presenting and diffusing study results.</p>}},
  author       = {{Anell, Anders and Svarvar, Patrick}},
  issn         = {{1170-7690}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{2}},
  pages        = {{175--185}},
  publisher    = {{Adis International}},
  series       = {{PharmacoEconomics}},
  title        = {{Pharmacoeconomics and clinical practice guidelines : A survey of attitudes in Swedish formulary committees}},
  url          = {{http://dx.doi.org/10.2165/00019053-200017020-00006}},
  doi          = {{10.2165/00019053-200017020-00006}},
  volume       = {{17}},
  year         = {{2000}},
}